79. Williams WW, Lu PJ, O’Halloran A, Bridges CB,
Kim DK, Pilishvili T, et al. Vaccination coverage
among adults, excluding influenza vaccination—
United States, 2013. MMWR Morb Mortal Wkly Rep
80. Centers for Disease Control and Prevention.
Human papillomavirus vaccination coverage among
adolescent girls, 2007-2012, and postlicensure vaccine
safety monitoring, 2006–2013 - United States. MMWR
Morb Mortal Wkly Rep 2013;62:591–5.
81. Binagwaho A, Wagner CM, Gatera M, Karema
C, Nutt CT, Ngabo F. Achieving high coverage in
Rwanda’s national human papillomavirus vaccination
programme. Bull World Health Organ 2012;90:623–8.
82. Accelerating HPV vaccine uptake: Urgency for action
to prevent cancer. A report to the President of the
United States from the President’s Cancer Panel.
Bethesda (MD): National Cancer Institute; 2014.
83. Graham DM, Isaranuwatchai W, Habbous S, de
Oliveira C, Liu G, Siu LL, et al. A cost-effectiveness
analysis of human papillomavirus vaccination of boys
for the prevention of oropharyngeal cancer. Cancer
84. Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal
PA, Golub TR, et al. AACR Cancer Progress Report
2012. Clin Cancer Res 2012;18:S1–100.
85. National Toxicology Program. Report on carcinogens,
thirteenth edition. Research Triangle Park (NC): U.S.
Department of Health and Human Services, Public
Health Service; 2014. Available from: http://ntp.niehs.
86. Radon and Cancer. 2011 Available from: http://www.
87. Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi
F, Bouvard V, Benbrahim-Tallaa L, et al. The
carcinogenicity of outdoor air pollution. Lancet Oncol
88. Centers for Disease Control and Prevention. CDC
vital signs: Colorectal cancer. Atlanta (GA): Centers
for Disease Control and Prevention; 2014. Available
89. Rebbeck TR. Precision prevention of cancer. Cancer
Epidemiol Biomarkers Prev 2014;23:2713–5.
90. Tufts Center for the Study of Drug Development. Cost
to develop and win marketing approval for a new
drug is $2.6 billion. [News release; cited 2015 Jul 31].
Available from: http://csdd.tufts.edu/news/complete_
91. Avorn J. The $2.6 billion pill—methodologic and
policy considerations. N Engl J Med 2015;372:1877–9.
92. Herbst RS, Gandara DR, Hirsch FR, Redman MW,
LeBlanc M, Mack PC, et al. Lung Master Protocol
(Lung-MAP)—A Biomarker-driven protocol for
accelerating development of therapies for squamous
cell lung cancer: SWOG S1400. Clin Cancer Res
93. National Cancer Institute. Molecular Analysis for
Therapy Choice Program (NCI-MATCH). [Cited
2015 Jul 31] Available from: http://www.cancer.gov/
94. Treon SP, Tripsas CK, Meid K, Warren D, Varma
G, Green R, et al. Ibrutinib in previously treated
Waldenstrom’s macroglobulinemia. N Engl J Med
95. Schiffman M, Wacholder S. Success of HPV
vaccination is now a matter of coverage. Lancet Oncol
96. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao
C, Mehlsen J, et al. A 9-valent HPV vaccine against
infection and intraepithelial neoplasia in women. N
Engl J Med 2015;372:711–23.
97. Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J,
Ferris D, et al. Attribution of 12 high-risk human
papillomavirus genotypes to infection and cervical
disease. Cancer Epidemiol Biomarkers Prev
98. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz
LE, Kohler B, et al. Annual Report to the Nation
on the Status of Cancer, 1975–2009, featuring the
burden and trends in human papillomavirus (
HPV)-associated cancers and HPV vaccination coverage
levels. J Natl Cancer Inst 2013;105:175–201.
99. Shaukat A, Mongin SJ, Geisser MS, Lederle FA,
Bond JH, Mandel JS, et al. Long-term mortality
after screening for colorectal cancer. N Engl J Med
100. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR,
Lavin P, Lidgard GP, et al. Multitarget stool DNA
testing for colorectal-cancer screening. N Engl J Med
101. Liu FF, Shi W, Done SJ, Miller N, Pintilie M, Voduc
D, et al. Identification of a low-risk luminal A breast
cancer cohort that may not benefit from breast
radiotherapy. J Clin Oncol 2015;33:2035–40
102. Early Breast Cancer Trialists’ Collaborative G, Darby
S, McGale P, Correa C, Taylor C, Arriagada R, et
al. Effect of radiotherapy after breast-conserving
surgery on 10-year recurrence and 15-year breast
cancer death: meta-analysis of individual patient data
for 10,801 women in 17 randomised trials. Lancet
103. Bellon JR. Personalized radiation oncology for breast
cancer: The new frontier. J Clin Oncol 2015;33:1998–2000.
104. Lord CJ, Ashworth A. The DNA damage response and
cancer therapy. Nature 2012;481:287–94.